.png){kind=icon}
.png){kind=icon}
Return
Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR Trial
.png){kind=icon}
PRE
AI
J
P
S
F
W
D
T
X
A
A
M
T
U
X
P
Z
R
K
K
R
Y
Z
B
G
T
DOI：10.1016/j.ophtha.2025.08.022.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
To follow up the previously published comparison of aflibercept 8 mg at extended dosing intervals versus aflibercept 2 mg every 8 weeks, in patients with neovascular age-related macular degeneration (nAMD) through 48 weeks, we now report efficacy, durability and safety analyses through 96 weeks.
Keywords:
aflibercept
neovascular age-related macular degeneration
extended dosing
efficacy
safety
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
9.5
Papers:
1.3W
Citations:
4.4W
Organization
Cited Papers